Viepram

VIEKIRA PAK: Effective Treatment for Chronic Genotype 1 Hepatitis C

VIEKIRA PAK is an all-oral, interferon-free treatment designed to cure chronic genotype 1 hepatitis C virus (HCV) infection. This medication includes three distinct mechanisms of action: an NS5A inhibitor, an NS3/4A protease inhibitor, and a non-nucleoside NS5B polymerase inhibitor. These components work together to inhibit the virus at multiple stages of its lifecycle, making it difficult for the virus to reproduce.

Key Features:

• High Efficacy: VIEKIRA PAK has been shown to cure 95-100% of GT1a and GT1b hepatitis C patients, including those with compensated cirrhosis, in clinical trials.
• Broad Patient Range: It is effective for both treatment-naive and experienced patients, as well as those with HCV/HIV-1 co-infection, liver transplant recipients with normal hepatic function, and those who have failed previous treatment with pegylated interferon and ribavirin.
• Contraindications: VIEKIRA PAK is not recommended for patients with moderate hepatic impairment (Child-Pugh B) and is contraindicated in patients with severe hepatic impairment (Child-Pugh C).

Dosage and Administration:

• Recommended Dosage: The recommended dosage is two ombitasvir, paritaprevir, ritonavir tablets once daily, and one dasabuvir tablet twice daily, taken with a meal.
• Ribavirin Combination: For certain patient populations, including those with cirrhosis or liver transplant recipients, VIEKIRA PAK is used in combination with ribavirin. The recommended dosage of ribavirin is based on weight: 1000 mg/day for subjects ?75 kg and 1200 mg/day for those >75 kg.

Important Safety Information:

• HBV Testing: Before starting treatment, all patients should be tested for HBV infection by measuring HBsAg and anti-HBc.
• Hepatic Decompensation: Assess for laboratory and clinical evidence of hepatic decompensation before initiating therapy.

VIEKIRA PAK is a prescription medicine used to treat adults with genotype 1 chronic hepatitis C virus infection, including those with compensated cirrhosis. It is essential to consult a healthcare provider before taking VIEKIRA PAK, especially if you have cirrhosis or other underlying liver conditions. When used with ribavirin, it is crucial to read the Medication Guide that comes with ribavirin, especially the important pregnancy information.